SCHEMBL5218314

SCHEMBL5218314

c1ccc(COc2cccc(-n3cc(-c4cnc5ccccc5n4)cn3)c2)cc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRM4 Q14833 2/20 0.54
MKNK1 Q9BUB5 6/20 0.51
MAPT P10636 3/20 0.45
ALKBH1 Q13686 1/20 0.43
EGLN1 Q9GZT9 1/20 0.43
KDM4E B2RXH2 2/20 0.42
NPC1 O15118 2/20 0.42
MEN1 O00255 1/20 0.42
ESR1 P03372 1/20 0.42
HTT P42858 1/20 0.42
RAB9A P51151 1/20 0.42
KMT2A Q03164 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
GRM5 P41594 2/20 0.42
FGFR1 P11362 1/20 0.41
FGFR2 P21802 1/20 0.41
FGFR4 P22455 1/20 0.41
FGFR3 P22607 1/20 0.41
KDR P35968 1/20 0.41
MKNK2 Q9HBH9 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5216715 0.86 ALDH1A1 (0.48) GRM4MKNK1MAPTKDM4ENPC1
SCHEMBL5215503 0.85 GRM4 (0.53) GRM4MKNK1MAPTALKBH1EGLN1
SCHEMBL5216692 0.84 MKNK1 (0.57) GRM4MKNK1MAPTNPC1RAB9A
SCHEMBL5216495 0.82 GRM4 (0.54) GRM4MAPTKDM4ENPC1RAB9A
SCHEMBL8353703 0.81 BCHE (0.51) GRM4MAPTNPC1MEN1RAB9A
SCHEMBL5216682 0.81 FGFR1 (0.49) GRM4MKNK1MAPTKDM4ENPC1
SCHEMBL5219398 0.80 GRM4 (0.52) GRM4MKNK1MAPTALKBH1EGLN1
SCHEMBL5216483 0.80 BRD4 (0.47) GRM4MAPTKDM4ENPC1HTT
SCHEMBL29589569 0.79 NPC1 (0.41) GRM4MKNK1MAPTKDM4ENPC1
SCHEMBL27091118 0.79 NPC1 (0.41) GRM4MKNK1MAPTKDM4ENPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1458383-B1 HETEROARYL SUBSTITUTED PYRAZOLE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 MERCK & CO INC (US) 2007-11-21 EP claimed
EP-1458383-A4 HETEROARYL SUBSTITUTED PYRAZOLE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 MERCK & CO INC (US) 2005-05-25 EP claimed
US-20050026963-A1 Heteroaryl substituted pyrazole modulators of metabotropic glutamate receptor-5 MERCK SHARP & DOHME LLC 2005-02-03 US claimed
EP-1458383-A2 HETEROARYL SUBSTITUTED PYRAZOLE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 Merck & Co., Inc. (US) 2004-09-22 EP claimed
WO-2004030637-A2 TREATMENT OF OBESITY AND OTHER DISORDERS ASSOCIATED WITH EXCESSIVE FOOD INTAKE MERCK & CO., INC. (US) 2004-04-15 WO claimed
WO-2003051833-A2 HETEROARYL SUBSTITUTED PYRAZOLE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 MERCK & CO., INC. (US) 2003-06-26 WO claimed
US-7569592-B2 Heteroaryl substituted pyrazole modulators of metabotropic glutamate receptor-5 MERCK & CO., INC. (US) 2009-08-04 US disclosed
US-7569592-B2 Heteroaryl substituted pyrazole modulators of metabotropic glutamate receptor-5 MERCK & CO., INC. (US) 2009-08-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050026963-A1 Heteroaryl substituted pyrazole modulators of metabotropic glutamate receptor-5 GRM5, GRIK5, GRIN2C GRM4 8/4885MKNK1 893/4885MAPT 2547/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.